Alameda, CA-based Arriva Pharmaceuticals has rounded up $6 million in funding to advance its work on anti-inflammatory therapies for treating respiratory disease. The round was led by Nordic Biotech; MPM BioVentures also participated. CEO Sue Preston said the funding will be used to develop the company's recombinant
alpha-one antitrypsin for hereditary emphysema.
- see this release
PLUS: With help from Domain Associates, San Diego's Obalon Therapeutics has secured $4.7 million of a 7.7 million first round. Item
Related Articles:
Biotech, emerging markets are big VC targets. Report
Serial investors: Comforting figures for VC backers. Report
VC adds billions in its pursuit of biotech ventures. Report